HMGB1 and central nervous system cancer: To investigate if miR-129-2 directly targets HMGB1 in glioma cells, we amplified the wild-type HMGB1 3′UTR containing the predicted binding sites of miR-129-2, and its mutant version by the binding site mutagenesis was also constructed (Fig. 5a).